Galectin-3 and incident cognitive impairment in REGARDS, a cohort of blacks and whites

Anand Venkatraman, Peter Callas, Leslie A. McClure, Frederick Unverzagt, Garima Arora, Virginia Howard, Virginia G. Wadley, Mary Cushman, Pankaj Arora

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: The relationship between serum galectin-3 and incident cognitive impairment was analyzed in the Reasons for Geographic and Racial Differences in Stroke study. Methods: Baseline galectin-3 was measured in 455 cases of incident cognitive impairment and 546 controls. Galectin-3 was divided into quartiles based on the weighted distribution in the control group, and the first quartile was the referent. Results: There was an increasing odds of cognitive impairment across quartiles of galectin-3 (odds ratios, 1.00 [0.68–1.46], 1.45 [1.01–2.10], and 1.58 [1.10–2.27] relative to the quartile 1; P trend =.003) in an unadjusted model, which persisted after adjusting for age, sex, and race (P =.004). Adjustment for cardiovascular risk factors greatly attenuated this association (odds ratios, 0.97 [0.60–1.57], 1.52 [0.94–2.46], and 1.27 [0.76–2.12]; P =.15). The association differed by diabetes status (P interaction,.007). Among nondiabetics (293 cases, 411 controls), those with galectin-3 in the fourth compared with first quartile had an odds ratio of 1.6 (0.95–2.99; P trend,.02). In diabetics, the odds ratio was 0.23 (0.04–1.33). Discussion: Serum galectin-3 was associated with increased risk of incident cognitive impairment in a large cohort study of blacks and whites but only in nondiabetics.

Original languageEnglish (US)
Pages (from-to)165-172
Number of pages8
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Volume4
DOIs
StatePublished - Jan 1 2018

Fingerprint

Galectin 3
Odds Ratio
Serum
Cognitive Dysfunction
hydroquinone
Cohort Studies
Stroke
Control Groups

Keywords

  • Biomarkers
  • Cognitive impairment
  • Epidemiology
  • Galectin-3
  • Incidence
  • Risk factors

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Galectin-3 and incident cognitive impairment in REGARDS, a cohort of blacks and whites. / Venkatraman, Anand; Callas, Peter; McClure, Leslie A.; Unverzagt, Frederick; Arora, Garima; Howard, Virginia; Wadley, Virginia G.; Cushman, Mary; Arora, Pankaj.

In: Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 4, 01.01.2018, p. 165-172.

Research output: Contribution to journalArticle

Venkatraman, Anand ; Callas, Peter ; McClure, Leslie A. ; Unverzagt, Frederick ; Arora, Garima ; Howard, Virginia ; Wadley, Virginia G. ; Cushman, Mary ; Arora, Pankaj. / Galectin-3 and incident cognitive impairment in REGARDS, a cohort of blacks and whites. In: Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2018 ; Vol. 4. pp. 165-172.
@article{27c5e0b1e5884617aec461e4f17fa867,
title = "Galectin-3 and incident cognitive impairment in REGARDS, a cohort of blacks and whites",
abstract = "Introduction: The relationship between serum galectin-3 and incident cognitive impairment was analyzed in the Reasons for Geographic and Racial Differences in Stroke study. Methods: Baseline galectin-3 was measured in 455 cases of incident cognitive impairment and 546 controls. Galectin-3 was divided into quartiles based on the weighted distribution in the control group, and the first quartile was the referent. Results: There was an increasing odds of cognitive impairment across quartiles of galectin-3 (odds ratios, 1.00 [0.68–1.46], 1.45 [1.01–2.10], and 1.58 [1.10–2.27] relative to the quartile 1; P trend =.003) in an unadjusted model, which persisted after adjusting for age, sex, and race (P =.004). Adjustment for cardiovascular risk factors greatly attenuated this association (odds ratios, 0.97 [0.60–1.57], 1.52 [0.94–2.46], and 1.27 [0.76–2.12]; P =.15). The association differed by diabetes status (P interaction,.007). Among nondiabetics (293 cases, 411 controls), those with galectin-3 in the fourth compared with first quartile had an odds ratio of 1.6 (0.95–2.99; P trend,.02). In diabetics, the odds ratio was 0.23 (0.04–1.33). Discussion: Serum galectin-3 was associated with increased risk of incident cognitive impairment in a large cohort study of blacks and whites but only in nondiabetics.",
keywords = "Biomarkers, Cognitive impairment, Epidemiology, Galectin-3, Incidence, Risk factors",
author = "Anand Venkatraman and Peter Callas and McClure, {Leslie A.} and Frederick Unverzagt and Garima Arora and Virginia Howard and Wadley, {Virginia G.} and Mary Cushman and Pankaj Arora",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.trci.2018.03.006",
language = "English (US)",
volume = "4",
pages = "165--172",
journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",
issn = "2352-8737",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Galectin-3 and incident cognitive impairment in REGARDS, a cohort of blacks and whites

AU - Venkatraman, Anand

AU - Callas, Peter

AU - McClure, Leslie A.

AU - Unverzagt, Frederick

AU - Arora, Garima

AU - Howard, Virginia

AU - Wadley, Virginia G.

AU - Cushman, Mary

AU - Arora, Pankaj

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: The relationship between serum galectin-3 and incident cognitive impairment was analyzed in the Reasons for Geographic and Racial Differences in Stroke study. Methods: Baseline galectin-3 was measured in 455 cases of incident cognitive impairment and 546 controls. Galectin-3 was divided into quartiles based on the weighted distribution in the control group, and the first quartile was the referent. Results: There was an increasing odds of cognitive impairment across quartiles of galectin-3 (odds ratios, 1.00 [0.68–1.46], 1.45 [1.01–2.10], and 1.58 [1.10–2.27] relative to the quartile 1; P trend =.003) in an unadjusted model, which persisted after adjusting for age, sex, and race (P =.004). Adjustment for cardiovascular risk factors greatly attenuated this association (odds ratios, 0.97 [0.60–1.57], 1.52 [0.94–2.46], and 1.27 [0.76–2.12]; P =.15). The association differed by diabetes status (P interaction,.007). Among nondiabetics (293 cases, 411 controls), those with galectin-3 in the fourth compared with first quartile had an odds ratio of 1.6 (0.95–2.99; P trend,.02). In diabetics, the odds ratio was 0.23 (0.04–1.33). Discussion: Serum galectin-3 was associated with increased risk of incident cognitive impairment in a large cohort study of blacks and whites but only in nondiabetics.

AB - Introduction: The relationship between serum galectin-3 and incident cognitive impairment was analyzed in the Reasons for Geographic and Racial Differences in Stroke study. Methods: Baseline galectin-3 was measured in 455 cases of incident cognitive impairment and 546 controls. Galectin-3 was divided into quartiles based on the weighted distribution in the control group, and the first quartile was the referent. Results: There was an increasing odds of cognitive impairment across quartiles of galectin-3 (odds ratios, 1.00 [0.68–1.46], 1.45 [1.01–2.10], and 1.58 [1.10–2.27] relative to the quartile 1; P trend =.003) in an unadjusted model, which persisted after adjusting for age, sex, and race (P =.004). Adjustment for cardiovascular risk factors greatly attenuated this association (odds ratios, 0.97 [0.60–1.57], 1.52 [0.94–2.46], and 1.27 [0.76–2.12]; P =.15). The association differed by diabetes status (P interaction,.007). Among nondiabetics (293 cases, 411 controls), those with galectin-3 in the fourth compared with first quartile had an odds ratio of 1.6 (0.95–2.99; P trend,.02). In diabetics, the odds ratio was 0.23 (0.04–1.33). Discussion: Serum galectin-3 was associated with increased risk of incident cognitive impairment in a large cohort study of blacks and whites but only in nondiabetics.

KW - Biomarkers

KW - Cognitive impairment

KW - Epidemiology

KW - Galectin-3

KW - Incidence

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=85046699854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046699854&partnerID=8YFLogxK

U2 - 10.1016/j.trci.2018.03.006

DO - 10.1016/j.trci.2018.03.006

M3 - Article

AN - SCOPUS:85046699854

VL - 4

SP - 165

EP - 172

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

SN - 2352-8737

ER -